Results 171 to 180 of about 1,965,573 (268)

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

Arthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin, Candace H. Feldman, Claire E. H. Barber, Gabriel Fabreau, Jake Jennings, Scott Patten, Cheryl Barnabe, Inflammatory Arthritis‐Specific ACSC Consensus Process Working Group   +7 more
wiley   +1 more source

Clinical Characteristics and Concordance of Anti‐MDA5 Antibodies: A Multicenter Australian Study

Arthritis Care &Research, EarlyView.
Objective In Australia, anti‐MDA5 antibodies are exclusively tested by a line immunoblot assay (LIA). The clinical concordance of an LIA‐positive anti‐MDA5 result is unclear. We aimed to describe the clinical features and determine the clinical concordance of patients with anti‐MDA5 antibodies. Methods Electronic records of a multisite cohort (patients
Syed B. Ali, Thomas Khoo, Keeran Shivakumar, Adam Caroll, Lauren Hender, Dimitra Beroukas, Kim Griggs, Celina Jin, Theo De Malmanche, Jessica Day, Gabor Major, Vidya Limaye   +11 more
wiley   +1 more source

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

Arthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi, Roberta A. Berard, Jean‐Philippe Proulx‐Gauthier, Heinrike Schmeling, Michelle Batthish, Gilles Boire, Adam M. Huber, Dax G. Rumsey, Jaime Guzman, Gaëlle Chédeville, The CAPRI registry Investigators   +10 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio, Federica Davanzo, Caterina Ricordi, Milena Bond, Ruggiero Mascolo, Jacopo Mora, Alessandro Tomelleri, Angelo Fassio, Francesca Cuzzocrea, Sara Monti, Edoardo Conticini, Fabiola Atzeni, Paolo Delvino, Carlotta Nannini, Augusta Ortolan, Francesco Pollastri, Ester Vivaldelli, Chiara Marvisi, Paola Toniati, Antonio Brucato, Alessandra Milanesi, Francesca Regola, Enrico Tombetti, Lorenzo Dagna, Roberta Ramonda, Christian Dejaco, Luca Quartuccio, Carlo Salvarani, Roberto Padoan   +28 more
wiley   +1 more source

Real‐World Safety of Concomitant Colchicine and Statin Therapy

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the risk of clinically meaningful muscle‐ and liver‐related outcomes associated with concomitant colchicine–statin therapy in a real‐world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone.
Roni Meidan, Ranel Loutati, Dan Caspi, Ori Elkayam, Ran Abuhasira, Tali Eviatar   +5 more
wiley   +1 more source

Bas-Congo Virus: Another Deadly Virus?

Future Microbiology, 2013
Chiu, C., Fair, J., /Leroy, Eric
openaire   +3 more sources

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

Advanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal, Younan Ma, Asad Khanmohammed, Dipen Parande, Hanming Zhang, Saket Dolare, Juliet Chen, Apiwat Wangweerawong, Saswata Karmakar, Hongfeng Deng, Frank Koppenhagen, Shraddha Sharma, Eric Reyes, Sherry He, Lianne Boeglin, Caroline Woo, Azadeh Paksa, Ayed Allawzi, Anusha Dias, Gregory Troiano, Shrirang Karve, Frank DeRosa   +21 more
wiley   +1 more source

Virucidal Efficacy of Holder Pasteurization of Breast Milk in a Portable Device. [PDF]

Pathogens
Suchkov MI, Yakovchuk EV, Shustova EY, Sirazova DI, Zolotareva AD, Karpova EV, Aksenova EL, Sotskova SE, Kozlovskaya LI.   +8 more
europepmc   +1 more source